Medpace moves into Singapore with new central lab

By Zachary Brennan

- Last updated on GMT

Related tags: Laboratory, Medicine

Medpace moves into Singapore with new central lab
Medpace Laboratories, Singapore will serve and support new and existing Medpace pharmaceutical clients conducting clinical research in the rapidly expanding Asia Pacific region. 

With dedicated project management and logistic teams, the central lab is fully integrated into ClinTrak – Medpace’s global decision support technology, which allows for the transfer of real time data to support clinical studies.

CROs have increasingly been turning to Singapore as a gateway to the region, with Covance​, PPD​ and Parexel​ extending their operations to the Asian country.

The Medpace Singapore facilities have been equipped with identical instrumentation, and use the same reagent systems, calibration, QA process and SOPs as their counterparts in Cincinnati, Ohio; Leuven, Belgium; and Beijing, China. The lab will also provide routine safety, biomarker and reference methodologies identical to what is offered elsewhere.

The push into the Asia Pacific region comes nearly three months since Medpace was acquired by UK-based private equity firm Cinven for $915m​. Cinven previously discussed the potential for growth in Asia for the CRO, which targets smaller to mid-market biotech, pharma and medical device companies.

The expansion also comes as Medpace will collaborate with NephroGenex​ on a Phase III study of a diabetic kidney disease treatment.

All Medpace laboratories are directly supervised by full-time doctoral level laboratory professionals including MDs and PhDs with board certification in Pathology/Laboratory Medicine. Each lab location also maintains accreditation by the College of American Pathologists (CAP), and NGSP Level 1 and CDC Lipid Standardization (LSP) Part III programs, which provide Medpace with the ability to deliver consistent, identical and highly standardized laboratory analysis.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more